Staphylococcal Infection
13
0
0
12
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
31%
4 trials in Phase 3/4
58%
7 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (13)
Staphylokinase and ABO Group Phenotype: New Players in Staphylococcus Aureus Implant-associated Infections Development
Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children
Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants
A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)
Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)
The Utility of Levofloxacin-Rifampin in the Therapy of Prosthetic Joint Infection
Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"
Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections
Efficacy Study of Rapid Test to Prevent Hospital Transmission of Methicillin-Resistant Staphylococcus Aureus (MRSA)
MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial